title: Translational immunotoxicology of immunomodulatory monoclonal antibodies.
abstract: While immunomodulatory monoclonal antibodies (mAbs) have a wide therapeutic potential, exaggerated immunopharmacology may drive both acute and delayed immunotoxicity. The existing tools for immunotoxicity assessment do not accurately predict the full range of immunotoxicities observed in humans. New and optimized models, assays, endpoints and biomarkers in animals and humans are required to safeguard patients and allow them access to these often transformational therapies.
authors.affiliation: UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK. Electronic address: frank.brennan@ucb.com.
authors.forename: Frank R
authors.initials: FR
authors.lastname: Brennan
authors.affiliation: UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK.
authors.forename: Andrea
authors.initials: A
authors.lastname: Kiessling
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007155:Immunologic Factors / Q000633:toxicity*; D018675:Toxicity Tests; D057170:Translational Research, Biomedical
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors